Belbuca (Buprenorphine HCl) Patent Expiration, LOE Window & CMS Spending
Belbuca (Buprenorphine HCl) by Biodelivery Sciences International: FDA Orange Book LOE 2032-12-21, 12 AB generics, $202.0M 2024 CMS Part D & Medicaid spend, and 21 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Biodelivery Sciences International |
| FDA Application & Pathway | N207932 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2032-12-21 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 12 |
| 2024 CMS Total Public Spend | $202.0M |
| 2024 Medicare Part D Spend | $160.1M |
| 2024 Medicaid Spend | $41.9M |
| Reported Wholesale Price Change (CA SB 17) | 21 WAC filings (max 17.4% 2-yr change) |